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Abstract: Acrodermatitis continua of Hallopeau (ACH) is a rare, sterile pustular eruption of
one or more digits. The condition presents with tender pustules and underlying erythema on
the tip of a digit, more frequently arising on a finger than a toe. As far as classification, ACH
is considered a localized form of pustular psoriasis. The eruption typically occurs after local
trauma or infection, but such a history is not always present and various other etiologies have
been described including infectious, neural, inflammatory, and genetic causes. The natural
progression of ACH is chronic and progressive, often resulting in irreversible complications
such as onychodystrophy that can result in anonychia, as well as osteitis that can result in
osteolysis of the distal phalanges. Because of the rarity of ACH, there have been no
randomized controlled studies to evaluate therapies, resulting in an absence of standardized
treatment guidelines. In clinical practice, a wide variety of treatments have been attempted,
with outcomes ranging from recalcitrance to complete resolution. In recent years, the
introduction of biologics has provided a new class of therapy that has revolutionized the
treatment of ACH. Specifically, rapid and sustained responses have been reported with the
use of anti-tumor necrosis factor agents like infliximab, adalimumab, and etanercept; IL-17
inhibitors like secukinumab; IL-12/23 inhibitors like ustekinumab; and IL-1 inhibitors like
anakinra. Nevertheless, there remains a considerable need for more research into treatment
for the benefit of individual patients with ACH as well as for the clinical knowledge gained
by such efforts. The purpose of this review is to provide a comprehensive overview of the
key features of ACH as well as a discussion of clinical management strategies for this unique
and debilitating condition.
Keywords: acrodermatitis continua of Hallopeau, psoriasis, pustular psoriasis, generalized
pustular psoriasis, palmoplantar pustulosis
Introduction
Acrodermatitis continua of Hallopeau (ACH) is a rare, chronic, sterile pustular
eruption of one or more digits. This entity has also been called pustular acroder-
matitis, acrodermatitis continua suppurativa, dermatitis perstans, acropustulosis,
acrodermatitis perstans, and dermatitis repens.1–4
ACH presents with tender, sterile pustules and underlying erythema on the tip of
a digit, more frequently arising on a finger than a toe.1,5 The eruption typically
occurs after local trauma or infection,6–8 however, such a history is not always
present4 and neural and inflammatory etiologies have also been described.5 ACH
always involves the nail apparatus; if there is no nail involvement, then alternative
diagnoses such as palmoplantar pustulosis (PPP) should be considered.6 Over time,
ACH becomes chronic and can exhibit proximal progression, extending to the
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dorsal aspect of the hand or the foot.7 Without successful
treatment, ACH can lead to several complications, includ-
ing onychodystrophy that can result in anonychia as well
as osteitis that can result in osteolysis of the distal
phalanges.4,5,7–9 In these ways, ACH can cause profound
disability and have a tremendously negative impact on
quality of life in these patients.
As far as classification, ACH is considered a localized
form of pustular psoriasis.2,5,10 It appears to be most
common in middle-aged females, but due to the overall
rarity of ACH, epidemiological information is limited to
anecdotal case reports.6,9,11,12 Relatedly, there are no stan-
dardized guidelines for treating ACH, but rather various
case reports with a wide range of therapeutic approaches
and outcomes.
The purpose of this review is to provide a comprehen-
sive overview of the key features of ACH as well as a
discussion of clinical management strategies for this
unique and debilitating condition.
Methods
This review is based on a literature search in MEDLINE
and Embase databases. The search was performed in
February 2019. The following keywords were used:
“Acrodermatitis continua of hallopeau,” “acrodermatitis
continua,” “dermatitis repens,” “acrodermatitis perstans,”
“Hallopeau*,” AND “psoria*.” Only articles written in
English were included, and no restrictions were set on
study type. No institutional review board approval was
required for this review article.
Results
Pathophysiological mechanisms
As mentioned, various etiologies have been described for
ACH, including traumatic, infectious, neural, and inflam-
matory causes.5 In the majority of case reports, the patient
recalls a minor trauma or infection preceding symptoms in
the same location; however, many patients deny such pre-
cipitating factors.9,13
In recent years, several studies have suggested genetic
causes of ACH. For example, two papers published in
2011 reported mutations in the IL36RN gene among
patients with pustular psoriasis.14,15 IL36RN is amply
expressed in the skin and belongs to the IL-1 cytokine
family that is involved in the innate immune system.
Several IL36 isoforms (IL-36α, IL-36β, and IL-36γ)
induce cytokines that contribute to a pro-inflammatory
cascade by binding to the IL-1 RL2 receptor and initiating
the recruitment and localization of T cells, neutrophils, and
dendritic cells to the skin.10,14–16 The IL36RN gene
encodes the IL36 receptor agonist (IL-36Ra), which nor-
mally acts to inhibit such pro-inflammatory signaling.
Mutations in IL36RN can thereby lead to unregulated
secretion of inflammatory cytokines,14,15,17 and such muta-
tions have been found in several cases of familial general-
ized pustular psoriasis (GPP). This inherited form is now
known as DITRA, ie, “Deficiency of Interleukin-Thirty six
Receptor Antagonist.” The authors of these papers suggest
that such genetic mutations may also be related to other
forms of pustular psoriasis such as ACH.10,15,18
In 2013, a team of researchers identified a homozygous
missense mutation in IL36RN in a male patient with ACH
as well as his female sibling with GPP, confirming that
these two diseases are likely related.10 Genetic linkages
are also seen within single patients; for example, a 2019
study identified nine patients with both ACH and GPP and
four patients with both ACH and PPP.19 Such reports are
further supported by additional studies confirming the
genotype–phenotype correlation between IL36RN muta-
tions and GPP, PPP, and ACH.17,20–22 As of May 2017, a
total of 16 IL36RN mutations had been discovered, and
these disease alleles are now believed to account for
approximately 20% of ACH cases.6
While IL36RN mutations are the most frequent genetic
abnormality in pustular forms of psoriasis,19 CARD14 and
AP1S3 have also been identified as causative or suscept-
ibility genes in ACH.20,23,24 First, CARD14 encodes pro-
teins produced by keratinocytes, and gain-of-function
mutations lead to increased activation of nuclear factor-
kappa B signaling and production of tumor necrosis fac-
tor-alpha (TNF-α),8 which has been identified in association
with ACH as well as GPP, PPP, and psoriasis vulgaris
(PV).25–28 Second, AP1S3 plays a role in vesicular traffick-
ing within keratinocytes, and loss-of-function mutations
cause abnormal autophagy, increased activation of TNF-α,
and overexpression IL36α.8 Variants in AP1S3 have been
described to contribute to ACH as well as GPP and
PPP.23,29 Interestingly, preliminary research suggests that
patients with ACH are more likely to carry two distinct
mutations (ie, IL36RN and AP1S3 or IL36RN and
CARD14) than patients affected by other forms of pustular
psoriasis,19,26,29,30 but there is a need for more investigation
in this area.
In summary, current evidence demonstrates that ACH
is associated with a variety of genetic mutations in the
Smith et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
Psoriasis: Targets and Therapy 2019:966
genes IL36RN, CARD14, and AP1S3. Mutations in these
same genes are associated with phenotypically related
pustular skin conditions such as GPP and PPP.
Clinical features
Symptoms of ACH typically begin with the tip of one digit
turning erythematous and developing painful pustules that
migrate under the nail bed and matrix, leading to
onychodystrophy.1,3 In the acute phase, the pustules rup-
ture and coalesce to form “a lake of pus that carries the
nail away,” as this condition is classically described.1,5
The resulting anonychia leaves behind an erythematous,
shiny, and smooth distal digit where pustules often
reform.18,31 As the disease progresses, the affected digits
can become hyperkeratotic with psoriasiform scaling and
continuing pustulation.5 In longstanding cases, ACH can
progress to involve additional digits or extend proximally
to the dorsal hand or foot; however, the disease typically
remains localized to the digit(s) for months or years before
such proximal progression.5,32 These clinical findings are
seen in Figure 1, which illustrate a classic case of
chronic ACH.
Rarely, the disease can cause osteitis of the underlying
phalanges, resulting in osteolysis in severe cases.3,5,31,33,34
Very rarely, ACH has been reported to result in acquired
syndactyly, likely due to ACH lesions causing loss of
interdigital epidermis and allowing for healing with fusion
of adjacent tissues.4,35
There are several aspects of ACH’s clinical features
that support its classification as a variant of pustular
psoriasis. First, the previously described genetic muta-
tions common to patients with ACH, GPP, and PPP
suggest these conditions are on the same autoimmune
inflammatory spectrum. Second, several authors have
reported the development of joint pain and arthritis in
patients with ACH.3,33,34 Soft tissue and bone involve-
ment, often revealed on X-ray imaging, further supports
the association of ACH with psoriasis and associated
arthritis. Third, there have been instances of geographic
tongue in patients with ACH, which is a finding consis-
tent with other forms of pustular psoriasis and other
inflammatory conditions.36 Lastly, ACH can progress to
GPP, particularly the life-threatening von Zumbusch
type.4,5,32,37,38 Such patterns of progression highlight the
critical importance of recognizing ACH as a localized
form of pustular psoriasis that is unique, can rapidly
evolve, and must be aggressively treated to prevent
complications.
Differential diagnosis
ACH is commonly misdiagnosed. Based on clinical pre-
sentation, its purulence can imitate bacterial, fungal, or
viral paronychia.11 Depending on the patient’s age and
comorbidities, secondarily infected contact dermatitis,
dyshidrotic eczema, or a paraneoplastic process are rea-
sonable possibilities.4 Furthermore, other infections of the
digits such as herpetic whitlow can present with vesiculo-
pustules while dermatophytosis can present with scaly
erythema, both resembling ACH. Autoimmune conditions
such as pemphigus vulgaris can imitate ACH by present-
ing with inflammation and erosions of the digits. In a
review by Seghal et al, the authors warn that late clinical
manifestations of ACH may necessitate evaluations for a
number of conditions including squamous cell carcinoma,
melanoma, pyogenic granuloma, Reiter’s disease,
Figure 1 Right foot of a 64-year-old patient who first presented with asymmetric dactylitis characterized by erythema and tenderness of the first, third, and fourth distal
interphalangeal joints with associated nail deformities. Written informed consent was obtained to take and publish the photographs above. Patient reported a history of
possible osteomyelitis diagnosed by primary care provider, but this diagnosis was not supported by imaging, and symptoms progressed despite antibiotic treatment. Initially
treated with topical steroids, resulting in preliminary improvement of skin changes. Approximately, 6 months after skin changes began, patient was found to have the findings
documented in these figures. The clinical history and presentation of pustules, scale, erythema, and nail dystrophy of the first, third, and fourth digits were consistent with
chronic Acrodermatitis continua of Hallopeau.
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subungual fibroma, glomus tumor, blastomycosis, and
onychomycosis.5
The most important condition to compare and contrast
with ACH is PPP. Fortunately, several key features help
distinguish these related conditions. First, ACH often fol-
lows trauma, as previously described, whereas PPP rarely
involves a history of injury. Second, suppurative nail
involvement is an early and defining feature of ACH
whereas PPP does not always affect the nails and is
usually non-suppurative.6 Third, ACH most commonly
remains unilateral and localized to a limited number of
digits and with an irregular distribution for many years,
while PPP is most commonly bilateral and symmetrical.2
Lastly, features such as soft tissue sclerosis and osteolysis
as described in ACH are not reported in PPP.39
Overall, the similarities between ACH with many other
conditions, especially PPP, necessitate a careful considera-
tion of a broad differential diagnosis and a thorough clin-
ical workup, as appropriate.
Histopathology
While the diagnosis of ACH is primarily clinical, based on
the history and clinical findings described, skin and nail
biopsies with staining and cultures can be helpful to
exclude other conditions in the differential.12 ACH
appears histologically very similar to pustular psoriasis,
with subcorneal neutrophilic pustules, spongiform pus-
tules, and moderate lymphohistiocytic infiltrate.1,4,5
Chronic ACH lesions usually show severe atrophy of the
papillary dermis and thinning of the epidermis.5 The nail
matrix is always involved and typically exhibits moderate
acanthosis, lymphocytic and neutrophilic exocytosis, and
spongiosis.40 Lastly, bacterial cultures are routinely sterile
but can yield predominant growth of commensals, which
is interpreted as non-contributory to the pathogenesis of
this non-infectious inflammatory disease.6
Management
ACH is characteristically chronic and recalcitrant in nat-
ure, and spontaneous improvement has rarely been
observed.2,5,12,32 Furthermore, the condition is so rare
that there have been no controlled studies to evaluate
therapies, resulting in an absence of standardized treatment
guidelines.12 As a result, many therapeutic options have
been attempted, with equivocal results as described in case
reports.5
Historically, the most common therapies for ACH have
been similar to treatments for other forms of psoriasis,
especially PPP,1,5,12,31 including topical and oral
corticosteroids,5,41 topical vitamin D analogs,42–45 topical
fluorouracil,46,47 topical calcineurin inhibitors,48 tar,5 topi-
cal and systemic retinoids,39,49,50 cyclosporine,51–54
methotrexate,48,55,56 and phototherapy or photochemo-
therapy.5 In addition, granulocyte and monocyte adsorp-
tion apheresis has been attempted in ACH, with promising
results in a small number of patients and far fewer side
effects than some of the more traditional therapies.57–60
In most reported cases, a combination of these modal-
ities is used (ie, systemic oral medication plus a topical
applied to the affected area), with clinical responses ran-
ging from recalcitrance to complete resolution.5 Nail
lesions are typically more difficult to manage than skin,61
and recurrence is common with decrease in dosing or
cessation of treatment.5 Furthermore, the potential toxici-
ties associated with several of these systemic therapies can
prevent or limit the duration of treatment in certain indi-
viduals, especially children and elderly patients with
ACH.5,62–64
In recent years, the introduction of biologics has pro-
vided a new class of therapy that has revolutionized the
treatment of ACH.5 Specifically, rapid and sustained
responses have been reported with the use of anti-TNF
agents like infliximab,55,65,66 adalimumab,67–71 and
etanercept,72–77 IL-17 inhibitors like secukinumab,78–80
IL-12/23 inhibitors like ustekinumab,81,82 and IL-1 inhibi-
tors like anakinra.83 Furthermore, the identification of
IL36RN mutations as a genetic contributor to ACH has
informed the development of biologics that specifically
block IL-36 signaling.19 A 2017 paper described a high
affinity, anti-human IL-36 receptor antagonist antibody
that was initially tested in vitro and shown to directly
inhibit IL-36-R-mediated signaling and inflammatory
cytokine production in primary human keratinocytes and
dermal fibroblases.84 Following this work, a Phase I proof-
of-concept study among seven patients with GPP treated
with this anti-IL-36 monoclonal antibody showed signifi-
cant improvement in symptoms.85 Interestingly, the anti-
IL-36 treatment was equally effective regardless of the
absence or presence of an IL36RN mutation, suggesting
the IL-36 pathway can be pathogenic regardless of a
patient’s genetic background.8,84,85
The use of both existing and emerging biologic agents
to treat ACH, especially cases that are refractory to tradi-
tional treatments, is an area of ongoing research and devel-
opment. No single agent has yet been identified as superior
for ACH, but several have demonstrated efficacy,
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representing a promising new chapter for managing this
chronic and often debilitating disease.
Discussion
These results demonstrate that ACH is a rare condition
that is genetically and phenotypically related to other
forms of pustular psoriasis but distinct in several dimen-
sions that influence clinical outcomes. The relatively
sparse number of case reports and consequent lack of
epidemiological or controlled studies can make this con-
dition particularly difficult for clinicians to manage.
Fortunately, biologic agents offer a new treatment option
with overwhelmingly positive results, especially in recal-
citrant and refractory cases.5
Nevertheless, there remains a need for more targeted
research on the causes and management of ACH. First, the
knowledge gained by identifying genetic mutations as a
cause of ACH needs to be harnessed to develop more
targeted treatment options. For example, IL36RN muta-
tions result in defects in IL-1 signaling, as discussed.
This elucidates why agents like anakinra (an IL-1 antago-
nist) have been reported as successful in treating ACH, but
optimal treatment may require developing agents that spe-
cifically target IL-36 or common pathways between IL-1
and IL-36.8,10 As such research moves forward, it will be
critical to recruit patients with ACH who have different
genetic backgrounds to determine the efficacy of these
new agents across the spectrum of genetic profiles, includ-
ing patients with no identified mutations.
Second, genetic studies have revealed strong associa-
tions between IL36RN mutations but have also uncovered
variants in other genes among patients with ACH, such as
CARD1421 and AP1S3.20 These findings suggest a more
complicated genetic picture to this disease beyond
IL36RN, and there is a need for additional studies to
more fully characterize its genetic underpinnings.
Third and perhaps most importantly, the rarity of
ACH has thus far prevented rigorous research to estab-
lish evidence-based treatment guidelines. Given the pain
and disfigurement caused by ACH, the potential for
serious and irreversible complications, and the associa-
tion of this rare variant with life-threatening forms of
pustular psoriasis, there remains considerable need for
more research into treatment for the benefit of individual
patients with ACH as well as for the clinical knowledge
gained by such efforts.
Disclosure
Tina Bhutani has received research funding from the
National Psoriasis Foundation and has served as a research
investigator and a consultant for Eli Lilly, Janssen, Merck,
Celgene and Regeneron. Wilson Liao is funded in part by
grants from the National Institutes of Health
(R01AR065174, U01AI119125) and has served as a
research investigator for Abbvie, Amgen, Janssen,
Novartis, Pfizer and Regenero. The authors report no
other conflicts of interest in this work.
References
1. Mengesha YM, Bennett ML. Pustular skin disorders: diagnosis and
treatment. Am J Clin Dermatol. 2002;3(6):389–400. doi:10.2165/
00128071-200203060-00003
2. Benjegerdes KE, Hyde K, Kivelevitch D, Mansouri B. Pustular
psoriasis: pathophysiology and current treatment perspectives.
Psoriasis (Auckl). 2016;6:131–144. doi:10.2147/PTT.S98954
3. Jo SJ, Park JY, Yoon HS, Youn JI. Case of acrodermatitis continua
accompanied by psoriatic arthritis. J Dermatol. 2006;33(11):787–
791. doi:10.1111/j.1346-8138.2006.00180.x
4. Waller JM, Wu JJ, Murase JE, Dyson SW, Kelly KM. Chronically
painful right thumb with pustules and onycholysis. Diagnosis: acro-
dermatitis continua of Hallopeau. Clin Exp Dermatol. 2007;32
(5):619–620. doi:10.1111/j.1365-2230.2007.02440.x
5. Sehgal VN, Verma P, Sharma S, et al. Acrodermatitis continua of
Hallopeau: evolution of treatment options. Int J Dermatol. 2011;50
(10):1195–1211. doi:10.1111/j.1365-4632.2011.04993.x
6. Navarini AA, Burden AD, Capon F, et al. European consensus state-
ment on phenotypes of pustular psoriasis. J Eur Acad Dermatol
Venereol. 2017;31(11):1792–1799. doi:10.1111/jdv.14386
7. Hoegler KM, John AM, Handler MZ, Schwartz RA. Generalized
pustular psoriasis: a review and update on treatment. J Eur Acad
Dermatol Venereol. 2018;32(10):1645–1651. doi:10.1111/jdv.14949
8. Bachelez H. Pustular psoriasis and related pustular skin diseases. Br J
Dermatol. 2018;178(3):614–618. doi:10.1111/bjd.16232
9. Yerushalmi J, Grunwald MH, Hallel-Halevy D, Avinoach I, Halevy
S. Chronic pustular eruption of the thumbs. Diagnosis: acrodermatitis
continua of Hallopeau (ACH). Arch Dermatol. 2000;136(7):925–930.
10. Abbas O, Itani S, Ghosn S, et al. Acrodermatitis continua of
Hallopeau is a clinical phenotype of DITRA: evidence that it is a
variant of pustular psoriasis. Dermatology. 2013;226(1):28–31.
doi:10.1159/000346572
11. Rosenberg BE, Strober BE. Acrodermatitis continua. Dermatol
Online J. 2004;10(3):9.
12. Korman AM, Rzepka PV, Sopkovich JA. Acrodermatitis continua of
Hallopeau. JAMA Dermatol. 2018;154(11):1346. doi:10.1001/
jamadermatol.2017.6195
13. Naldi L, Gambini D. The clinical spectrum of psoriasis. Clin
Dermatol. 2007;25(6):510–518. doi:10.1016/j.clindermatol.2007.
08.003
14. Onoufriadis A, Simpson MA, Pink AE, et al. Mutations in IL36RN/
IL1F5 are associated with the severe episodic inflammatory skin
disease known as generalized pustular psoriasis. Am J Hum Genet.
2011;89(3):432–437. doi:10.1016/j.ajhg.2011.07.022
15. Marrakchi S, Guigue P, Renshaw BR, et al. Interleukin-36-receptor
antagonist deficiency and generalized pustular psoriasis. N Engl J
Med. 2011;365(7):620–628. doi:10.1056/NEJMoa1013068
Dovepress Smith et al
Psoriasis: Targets and Therapy 2019:9 submit your manuscript | www.dovepress.com
DovePress
69
16. O’Keefe E, Braverman IM, Cohen I. Annulus migrans. Identical
lesions in pustular psoriasis, Reiter’s syndrome, and geographic ton-
gue. Arch Dermatol. 1973;107(2):240–244.
17. Tauber M, Bal E, Pei XY, et al. IL36RN mutations affect protein
expression and function: a basis for genotype-phenotype correlation
in pustular diseases. J Invest Dermatol. 2016;136(9):1811–1819.
doi:10.1016/j.jid.2016.04.038
18. Haneke E. Nail psoriasis: clinical features, pathogenesis, differential
diagnoses, and management. Psoriasis (Auckl). 2017;7:51–63.
doi:10.2147/PTT.S126281
19. Twelves S, Mostafa A, Dand N, et al. Clinical and genetic differences
between pustular psoriasis subtypes. J Allergy Clin Immunol.
2018;143(3):1021–1026.
20. Setta-Kaffetzi N, Navarini AA, Patel VM, et al. Rare pathogenic
variants in IL36RN underlie a spectrum of psoriasis-associated pust-
ular phenotypes. J Invest Dermatol. 2013;133:1366–1369.
doi:10.1038/jid.2012.490
21. Sugiura K. The genetic background of generalized pustular psoriasis:
IL36RN mutations and CARD14 gain-of-function variants. J Dermatol
Sci. 2014;74(3):187–192. doi:10.1016/j.jdermsci.2014.02.006
22. Liang J, Huang P, Li H, et al. Mutations in IL36RN are associated
with geographic tongue. Hum Genet. 2017;136(2):241–252.
doi:10.1007/s00439-016-1750-y
23. Setta-Kaffetzi N, Simpson MA, Navarini AA, et al. AP1S3 mutations
are associated with pustular psoriasis and impaired Toll-like receptor
3 trafficking. Am J Hum Genet. 2014;94(5):790–797. doi:10.1016/j.
ajhg.2014.04.005
24. Mossner R, Frambach Y, Wilsmann-Theis D, et al. palmoplantar
pustular psoriasis is associated with missense variants in CARD14,
but not with loss-of-function mutations in IL36RN in European
patients. J Invest Dermatol. 2015;135(10):2538–2541. doi:10.1038/
jid.2015.186
25. Korber A, Mossner R, Renner R, et al. Mutations in IL36RN in
patients with generalized pustular psoriasis. J Invest Dermatol.
2013;133(11):2634–2637. doi:10.1038/jid.2013.214
26. Berki DM, Liu L, Choon SE, et al. Activating CARD14 mutations
are associated with generalized pustular psoriasis but rarely account
for familial recurrence in psoriasis vulgaris. J Invest Dermatol.
2015;135(12):2964–2970. doi:10.1038/jid.2015.288
27. Jordan CT, Cao L, Roberson ED, et al. PSORS2 is due to mutations
in CARD14. Am J Hum Genet. 2012;90(5):784–795. doi:10.1016/j.
ajhg.2012.03.012
28. Sugiura K, Muto M, Akiyama M. CARD14 c.526G>C (p.
Asp176His) is a significant risk factor for generalized pustular psor-
iasis with psoriasis vulgaris in the Japanese cohort. J Invest
Dermatol. 2014;134(6):1755–1757. doi:10.1038/jid.2014.46
29. Mahil SK, Twelves S, Farkas K, et al. AP1S3 mutations cause skin
autoinflammation by disrupting keratinocyte autophagy and up-reg-
ulating IL-36 production. J Invest Dermatol. 2016;136(11):2251–
2259. doi:10.1016/j.jid.2016.06.618
30. Mossner R, Wilsmann-Theis D, Oji V, et al. The genetic basis for
most patients with pustular skin disease remains elusive. Br J
Dermatol. 2018;178(3):740–748. doi:10.1111/bjd.15867
31. Alorainy M, Alshaya M, Al-Rikabi A, Ayesh M, Alsaif F.
Acrodermatitis continua of Hallopeau with bone resorption in an 8-
year-old patient: a case report. Case Rep Dermatol. 2017;9(3):259–
264. doi:10.1159/000485370
32. Kim KH, Kim HL, Suh HY, et al. A case of acrodermatitis continua
accompanying with osteolysis and atrophy of the distal phalanx that
evoluted into generalized pustular psoriasis. Ann Dermatol. 2016;28
(6):794–795. doi:10.5021/ad.2016.28.6.794
33. Okuno H, Ogura K, Okuyama R, Itoi E. Two cases of acrodermatitis
continua of Hallopeau associated with generalized arthritis. Acta
Dermatovenerol Croat. 2013;21(4):265–267.
34. Mueller RB, Ogilvie A, Schwarz S, Kern P, Schett G, Sticherling M.
Adalimumab treatment of a patient with psoriasis suppurativa
Hallopeau associated osteoarthropathy. Clin Exp Rheumatol.
2009;27:887.
35. Kirkup ME, Lovell CR. Acquired syndactyly secondary to acroder-
matitis continua of Hallopeau. Br J Dermatol. 2005;152:1083–1084.
doi:10.1111/j.1365-2133.2005.06580.x
36. Sadlier M. Acrodermatitis continua of Hallopeau and geographic
tongue are variants of pustular psoriasis. JAAD Case Rep. 2018;4
(3):277. doi:10.1016/j.jdcr.2017.08.022
37. Baker H, Ryan TJ. Generalized pustular psoriasis. A clinical and
epidemiological study of 104 cases. Br J Dermatol. 1968;80
(12):771–793. doi:10.1111/j.1365-2133.1968.tb11947.x
38. Ranugha PS, Kumari R, Thappa DM. Acrodermatitis continua of
hallopeau evolving into generalised pustular psoriasis. Indian J
Dermatol. 2013;58(2):161. doi:10.4103/0019-5154.108096
39. Pearson LH, Allen BS, Smith JG Jr. Acrodermatitis continua of
Hallopeau: treatment with etretinate and review of relapsing pustu-
lar eruptions of the hands and feet. J Am Acad Dermatol. 1984;11(4
Pt 2):755–762.
40. Sehgal VN, Sharma S. Significance of Gram’s stain smear, potas-
sium hydroxide mount, culture, and microscopic pathology in the
diagnosis of acrodermatitis continua of Hallopeau. Skinmed. 2011;9
(4):260–261.
41. Sotiriadis D, Patsatsi A, Sotiriou E, Papagaryfallou I, Chrysomallis F.
Acrodermatitis continua of Hallopeau on toes successfully treated
with a two-compound product containing calcipotriol and betametha-
sone dipropionate. J Dermatolog Treat. 2007;18(5):315–318.
doi:10.1080/09546630701367118
42. Piraccini BM, Tosti A, Iorizzo M, Misciali C. Pustular psoriasis of the
nails: treatment and long-term follow-up of 46 patients. Br J Dermatol.
2001;144(5):1000–1005. doi:10.1046/j.1365-2133.2001.04189.x
43. Mozzanica N, Cattaneo A. The clinical effect of topical calcipotriol
in acrodermatitis continua of hallopeau. Br J Dermatol. 1998;138
(3):556. doi:10.1046/j.1365-2133.1998.02034.x
44. Emtestam L, Weden U. Successful treatment for acrodermatitis con-
tinua of Hallopeau using topical calcipotriol. Br J Dermatol.
1996;135(4):644–646.
45. Brill TJ, Elshorst-Schmidt T, Valesky EM, Kaufmann R, Thaci D.
Successful treatment of acrodermatitis continua of Hallopeau with
sequential combination of calcipotriol and tacrolimus ointments.
Dermatology. 2005;211(4):351–355. doi:10.1159/000088507
46. Fredriksson T. Topically applied fluorouracil in the treatment of
psoriatic nails. Arch Dermatol. 1974;110(5):735–736.
47. Tsuji T, Sugai T. Topically administered fluorouracil in psoriasis.
Arch Dermatol. 1972;105(2):208–212.
48. Wilsmann-Theis D, Hagemann T, Dederer H, Wenzel J, Bieber T,
Novak N. Successful treatment of acrodermatitis continua suppura-
tiva with topical tacrolimus 0.1% ointment. Br J Dermatol. 2004;150
(6):1194–1197. doi:10.1111/j.1365-2133.2004.05992.x
49. van Dooren-Greebe RJ, van de Kerkhof PC, Chang A, Happle R.
Acitretin monotherapy in acrodermatitis continua Hallopeau. Acta
Derm Venereol. 1989;69(4):344–346.
50. Slawsky LD, Libow LF. Successful treatment of acrodermatitis con-
tinua of Hallopeau with etretinate. J Am Acad Dermatol. 1990;23(6
Pt 1):1176–1178.
51. Zachariae H, Thestrup-Pedersen K. Ciclosporin A in acrodermatitis
continua. Dermatologica. 1987;175(1):29–32.
52. Harland CC, Kilby PE, Dalziel KL. Acrodermatitis continua
responding to cyclosporin therapy. Clin Exp Dermatol. 1992;17
(5):376–378.
53. Peter RU, Ruzicka T, Donhauser G, Braun-Falco O. Acrodermatitis
continua-type of pustular psoriasis responds to low-dose cyclospor-
ine. J Am Acad Dermatol. 1990;23(3 Pt 1):515–516.
Smith et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
Psoriasis: Targets and Therapy 2019:970
54. Georgakopoulos JR, Ighani A, Yeung J. Short- and long-term man-
agement of an acute pustular psoriasis flare: a case report. J Cutan
Med Surg. 2017;21(5):452–456. doi:10.1177/1203475417712499
55. Rubio C, Martin MA, Arranz Sanchez DM, Vidaurrazaga C, CasadoM.
Excellent and prolonged response to infliximab in a case of recalcitrant
acrodermatitis continua of Hallopeau. J Eur Acad Dermatol Venereol.
2009;23:707–708. doi:10.1111/j.1468-3083.2008.02998.x
56. Chowdhury MM, Motley RJ. Treatment of acrodermatitis continua of
Hallopeau with oral propylthiouracil and methotrexate. Clin Exp
Dermatol. 2001;26(8):657–660.
57. Sakanoue M, Takeda K, Kawai K, Kanekura T. Granulocyte and
monocyte adsorption apheresis for refractory skin diseases due to
activated neutrophils, psoriasis, and associated arthropathy. Ther
Apher Dial. 2013;17(5):477–483. doi:10.1111/1744-9987.12113
58. Seishima M, Mizutani Y, Shibuya Y, Nagasawa C, Aoki T. Efficacy
of granulocyte and monocyte adsorption apheresis for pustular psor-
iasis. Ther Apher Dial. 2008;12(1):13–18. doi:10.1111/j.1744-
9987.2007.00536.x
59. Shukuya R, Hasegawa T, Niwa Y, Okuma K, Ikeda S. Granulocyte
and monocyte adsorption apheresis for generalized pustular psoriasis.
J Dermatol. 2011;38(12):1130–1134. doi:10.1111/j.1346-
8138.2011.01279.x
60. Kanekura T, Hiraishi K, Kawahara K, Maruyama I, Kanzaki T.
Granulocyte and monocyte adsorption apheresis (GCAP) for refrac-
tory skin diseases caused by activated neutrophils and psoriatic
arthritis: evidence that GCAP removes Mac-1-expressing neutrophils.
Ther Apher Dial. 2006;10(3):247–256. doi:10.1111/j.1744-
9987.2006.00369.x
61. Iijima S, Okazaki Y, Watanabe S, Maruyama Y. Case of acroderma-
titis continua of Hallopeau following psoriasis with atypical clinical
presentation. J Dermatol. 2014;41(11):1006–1008. doi:10.1111/1346-
8138.12639
62. Hjorth N, Thomsen K. Parakeratosis pustulosa. Br J Dermatol.
1967;79(10):527–532. doi:10.1111/j.1365-2133.1967.tb11407.x
63. Chen P, Li C, Xue R, et al. Efficacy and safety of acitretin mono-
therapy in children with pustular psoriasis: results from 15 cases and
a literature review. J Dermatolog Treat. 2018;29(4):353–363.
doi:10.1080/09546634.2017.1395798
64. Kiszewski AE, De Villa D, Scheibel I, Ricachnevsky N. An infant
with acrodermatitis continua of Hallopeau: successful treatment with
thalidomide and UVB therapy. Pediatr Dermatol. 2009;26(1):105–
106. doi:10.1111/j.1525-1470.2008.00838.x
65. Mang R, Ruzicka T, Stege H. Successful treatment of acrodermatitis
continua of Hallopeau by the tumour necrosis factor-alpha inhibitor
infliximab (Remicade). Br J Dermatol. 2004;150:379–380. England.
doi:10.1111/j.1365-2133.2003.05761.x
66. Ahmad K, Rogers S. Three years’ experience with infliximab in
recalcitrant psoriasis. Clin Exp Dermatol. 2006;31(5):630–633.
doi:10.1111/j.1365-2230.2006.02170.x
67. Tobin AM, Kirby B. Successful treatment of recalcitrant acroderma-
titis continua of Hallopeau with adalimumab and acitretin. Br J
Dermatol. 2005;153:445–446. doi:10.1111/j.1365-2133.2005.06759.x
68. Ryan C, Collins P, Kirby B, Rogers S. Treatment of acrodermatitis
continua of Hallopeau with adalimumab. Br J Dermatol.
2009;160:203–205. doi:10.1111/j.1365-2133.2008.08893.x
69. Lefkir S, Slimani S, Brahimi N, Ladjouze-Rezig A. Successful treat-
ment of Acrodermatitis continua of Hallopeau associated with psor-
iatic arthritis with adalimumab. Eur J Rheumatol. 2015;2(2):78–79.
doi:10.5152/eurjrheum.2015.0072
70. Di Costanzo L, Napolitano M, Patruno C, Cantelli M, Balato N.
Acrodermatitis continua of Hallopeau (ACH): two cases successfully
treated with adalimumab. J Dermatolog Treat. 2014;25(6):489–494.
doi:10.3109/09546634.2013.848259
71. Sopkovich JA, Anetakis Poulos G, Wong HK. Acrodermatitis con-
tinua of hallopeau successfully treated with adalimumab. J Clin
Aesthet Dermatol. 2012;5(2):60–62.
72. Thielen AM, Barde C, Marazza G, Saurat JH. Long-term control with
etanercept (Enbrel) of a severe acrodermatitis continua of Hallopeau
refractory to infliximab (Remicade). Dermatology. 2008;217(2):137–
139. doi:10.1159/000134613
73. Bonish B, Rashid RM, Swan J. Etanercept responsive acrodermatitis
continua of Hallopeau: is a pattern developing? J Drugs Dermatol.
2006;5(9):903–904.
74. Nikkels AF, Pierard GE. Etanercept and recalcitrant acrodermatitis
continua of Hallopeau. J Drugs Dermatol. 2006;5(8):705–706.
75. Kazinski K, Joyce KM, Hodson D. The successful use of etanercept
in combination therapy for treatment of acrodermatitis continua of
hallopeau. J Drugs Dermatol. 2005;4(3):360–364.
76. Puig L, Barco D, Vilarrasa E, Alomar A. Treatment of acrodermatitis
continua of Hallopeau with TNF-blocking agents: case report and
review. Dermatology. 2010;220(2):154–158. doi:10.1159/000277415
77. Silpa-archa N, Wongpraparut C. A recalcitrant acrodermatitis con-
tinua of Hallopeau successfully treated with etanercept. J Med Assoc
Thai. 2011;94(9):1154–1157.
78. Balestri R, Rech G, Tasin L, Rizzoli L, Girardelli CR. Acrodermatitis
continua of Hallopeau successfully treated with secukinumab. J
Dermatolog Treat. 2018;29:1–7.
79. Baron JA. Acrodermatitis of Hallopeau and erosive oral mucositis
successfully treated with secukinumab. JAAD Case Rep. 2017;3
(3):215–218. doi:10.1016/j.jdcr.2017.02.016
80. Herrero-Moyano M, Capusan TM, Martinez-Mera C, Llamas-Velasco
M, Dauden E. Recalcitrant annular pustular psoriasis associated with
psoriatic arthritis successfully treated with secukinumab. JAAD Case
Rep. 2018;4(8):842–844. doi:10.1016/j.jdcr.2018.03.016
81. Adisen E, Ozer I, Temel B, Gurer MA. Ustekinumab for the treat-
ment of acrodermatitis continua of Hallopeau refractory to anti-TNF
agents. Dermatol Ther. 2017;30:2. doi:10.1111/dth.12460
82. Saunier J, Debarbieux S, Jullien D, Garnier L, Dalle S, Thomas L.
Acrodermatitis continua of Hallopeau treated successfully with usteki-
numab and acitretin after failure of tumour necrosis factor blockade and
anakinra. Dermatology. 2015;230(2):97–100. doi:10.1159/000367690
83. Lutz V, Lipsker D. Acitretin- and tumor necrosis factor inhibitor-
resistant acrodermatitis continua of hallopeau responsive to the inter-
leukin 1 receptor antagonist anakinra. Arch Dermatol. 2012;148
(3):297–299. doi:10.1001/archdermatol.2011.2473
84. Ganesan R, Raymond EL, Mennerich D, et al. Generation and func-
tional characterization of anti-human and anti-mouse IL-36R antago-
nist monoclonal antibodies. MAbs. 2017;9(7):1143–1154.
doi:10.1080/19420862.2017.1353853
85. Bachelez H, Choon SE, Marrakchi S, et al. Inhibition of the inter-
leukin-36 pathway for the treatment of generalized pustular psoriasis.
N Engl J Med. 2019;380(10):981–983. doi:10.1056/NEJMc1811317
Dovepress Smith et al
Psoriasis: Targets and Therapy 2019:9 submit your manuscript | www.dovepress.com
DovePress
71
Psoriasis: Targets and Therapy Dovepress
Publish your work in this journal
Psoriasis: Targets and Therapy is international, peer-reviewed, open
access journal focusing on psoriasis, nail psoriasis, psoriatic arthritis
and related conditions, identification of therapeutic targets and the
optimal use of integrated treatment interventions to achieve
improved outcomes and quality of life. Visit http://www.dovepress.
com/testimonials.php to read real quotes from published authors.
Submit your manuscript here: http://www.dovepress.com/psoriasis-targets-and-therapy-journal
Smith et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
Psoriasis: Targets and Therapy 2019:972
